Article
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Proceedings of the National Academy of Sciences of the United States of America - 27 Dec 2005
Lu Xiaohui, Levine Ross, Tong Wei, Wernig Gerlinde, Pikman Yana, Zarnegar Sara, Gilliland D Gary, Lodish Harvey
Abstract excerpt
A recurrent somatic activating mutation in the nonreceptor tyrosine kinase JAK2 (JAK2V617F) occurs in the majority of patients with the myeloproliferative disorders polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, and, less commonly, chronic myelomonocytic leukemia. We do not understand the basis for the specificity of the JAK2V617F mutation in clonal disorders of the myeloid,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.